Bioventix PLC (LON:BVXP – Get Free Report) insider Peter John Harrison bought 875 shares of Bioventix stock in a transaction that occurred on Tuesday, November 4th. The stock was bought at an average price of GBX 2,220 per share, with a total value of £19,425.
Bioventix Price Performance
BVXP traded down GBX 54 on Tuesday, hitting GBX 2,121. The company had a trading volume of 12,789 shares, compared to its average volume of 8,375. The company’s fifty day moving average price is GBX 2,372.35 and its 200 day moving average price is GBX 2,574.56. Bioventix PLC has a 1-year low of GBX 1,750 and a 1-year high of GBX 4,000. The stock has a market cap of £110.82 million, a price-to-earnings ratio of 14.32 and a beta of 0.35.
Bioventix (LON:BVXP – Get Free Report) last posted its earnings results on Monday, October 27th. The biotechnology company reported GBX 145.27 earnings per share for the quarter. Bioventix had a return on equity of 69.09% and a net margin of 59.51%. On average, sell-side analysts forecast that Bioventix PLC will post 166.3066955 EPS for the current year.
Bioventix Company Profile
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
See Also
- Five stocks we like better than Bioventix
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Prediction Markets Are Coming: Can DraftKings & FanDuel Survive?
- Best Stocks Under $10.00
- Shopify Pullback Sets Stage for 20% Rally to $200 Target
- The Risks of Owning Bonds
- Roku’s Profit Engine Roars to Life: Is the Rally Just Beginning?
Receive News & Ratings for Bioventix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix and related companies with MarketBeat.com's FREE daily email newsletter.
